<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Heart rates during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> and reperfusion are possible determinants of reperfusion <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We used ivabradine, a selective If current inhibitor, to assess the effects of heart rate reduction (HRR) during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-reperfusion on reperfusion <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and assessed potential anti-arrhythmic mechanisms by optical mapping </plain></SENT>
<SENT sid="2" pm="."><plain>Five groups of rat hearts were subjected to regional <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> by left anterior descending <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 8min followed by 10min of reperfusion: (1) Control n=10; (2) 1μM of ivabradine perfusion n=10; (3) 1μM of ivabradine+5Hz atrial pacing throughout <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-reperfusion n=5; (4) 1μM of ivabradine+5Hz pacing only at reperfusion; (5) 100μM of ivabradine was used as a 1ml bolus upon reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>For optical mapping, 10 hearts (ivabradine n=5; 5Hz pacing n=5) were subjected to global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> whilst transmembrane voltage transients were recorded </plain></SENT>
<SENT sid="4" pm="."><plain>Epicardial activation was mapped, and the rate of development of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced electrophysiological changes was assessed </plain></SENT>
<SENT sid="5" pm="."><plain>HRR observed in the ivabradine group during both <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> (195±11bpm vs. control 272±14bpm, p&lt;0.05) and at reperfusion (168±13bpm vs. 276±14bpm, p&lt;0.05) was associated with reduced reperfusion <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) incidence (20% vs. 90%, p&lt;0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Pacing throughout <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-reperfusion abolished the protective effects of ivabradine (100% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>), whereas pacing at reperfusion only partially attenuated this effect (40% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) </plain></SENT>
<SENT sid="7" pm="."><plain>Ivabradine, given as a bolus at reperfusion, did not significantly affect <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> incidence (80% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) </plain></SENT>
<SENT sid="8" pm="."><plain>Optical mapping experiments showed a delay to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced conduction slowing (time to 50% conduction slowing: 10.2±1.3min vs. 5.1±0.7min, p&lt;0.05) and to loss of electrical excitability in ivabradine-perfused hearts (27.7±4.3min vs. 14.5±0.6min, p&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Ivabradine administered throughout <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> and reperfusion reduced reperfusion <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> incidence through HRR </plain></SENT>
<SENT sid="10" pm="."><plain>Heart rate during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> is a major determinant of reperfusion <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Heart rate at reperfusion alone was not a determinant of reperfusion <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>, as neither a bolus of ivabradine nor pacing immediately prior to reperfusion significantly altered reperfusion <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> incidence </plain></SENT>
<SENT sid="12" pm="."><plain>This anti-arrhythmic effect of heart rate reduction during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> may reflect slower development of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced electrophysiological changes </plain></SENT>
</text></document>